432 related articles for article (PubMed ID: 33206174)
21. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
22. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
[TBL] [Abstract][Full Text] [Related]
23. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282
[TBL] [Abstract][Full Text] [Related]
24. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
[TBL] [Abstract][Full Text] [Related]
26. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
Levy AG; Zage PE; Akers LJ; Ghisoli ML; Chen Z; Fang W; Kannan S; Graham T; Zeng L; Franklin AR; Huang P; Zweidler-McKay PA
Invest New Drugs; 2012 Feb; 30(1):191-9. PubMed ID: 20890785
[TBL] [Abstract][Full Text] [Related]
27. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
28. Comparing mTOR inhibitor Rapamycin with Torin-2 within the RIST molecular-targeted regimen in neuroblastoma cells.
Waetzig R; Matthes M; Leister J; Penkivech G; Heise T; Corbacioglu S; Sommer G
Int J Med Sci; 2021; 18(1):137-149. PubMed ID: 33390782
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells.
Höglund A; Nilsson LM; Muralidharan SV; Hasvold LA; Merta P; Rudelius M; Nikolova V; Keller U; Nilsson JA
Clin Cancer Res; 2011 Nov; 17(22):7067-79. PubMed ID: 21933891
[TBL] [Abstract][Full Text] [Related]
30. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
[TBL] [Abstract][Full Text] [Related]
31. FGFR2 loss sensitizes MYCN-amplified neuroblastoma CHP134 cells to CHK1 inhibitor-induced apoptosis.
Ando K; Ohira M; Takada I; Cázares-Ordoñez V; Suenaga Y; Nagase H; Kobayashi S; Koshinaga T; Kamijo T; Makishima M; Wada S
Cancer Sci; 2022 Feb; 113(2):587-596. PubMed ID: 34807483
[TBL] [Abstract][Full Text] [Related]
32. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
[TBL] [Abstract][Full Text] [Related]
33. Suppression of leukemia development caused by PTEN loss.
Guo W; Schubbert S; Chen JY; Valamehr B; Mosessian S; Shi H; Dang NH; Garcia C; Theodoro MF; Varella-Garcia M; Wu H
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1409-14. PubMed ID: 21212363
[TBL] [Abstract][Full Text] [Related]
34. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
35. Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Ridges S; Heaton WL; Joshi D; Choi H; Eiring A; Batchelor L; Choudhry P; Manos EJ; Sofla H; Sanati A; Welborn S; Agarwal A; Spangrude GJ; Miles RR; Cox JE; Frazer JK; Deininger M; Balan K; Sigman M; Müschen M; Perova T; Johnson R; Montpellier B; Guidos CJ; Jones DA; Trede NS
Blood; 2012 Jun; 119(24):5621-31. PubMed ID: 22490804
[TBL] [Abstract][Full Text] [Related]
36. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
Carroll WL; Aifantis I; Raetz E
Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
[TBL] [Abstract][Full Text] [Related]
37. Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Evageliou NF; Haber M; Vu A; Laetsch TW; Murray J; Gamble LD; Cheng NC; Liu K; Reese M; Corrigan KA; Ziegler DS; Webber H; Hayes CS; Pawel B; Marshall GM; Zhao H; Gilmour SK; Norris MD; Hogarty MD
Clin Cancer Res; 2016 Sep; 22(17):4391-404. PubMed ID: 27012811
[TBL] [Abstract][Full Text] [Related]
38. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
39. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.
Sarmento LM; Póvoa V; Nascimento R; Real G; Antunes I; Martins LR; Moita C; Alves PM; Abecasis M; Moita LF; Parkhouse RM; Meijerink JP; Barata JT
Oncogene; 2015 Jun; 34(23):2978-90. PubMed ID: 25132270
[TBL] [Abstract][Full Text] [Related]
40. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
